Dyslipidemia in psoriasis: as a risk for cardiovascular disease

Priya Hilda Dsouza, Maria Kuruville


Background: Psoriasis is a common and recurrent proliferative inflammatory skin disease that has been associated with abnormal plasma lipid metabolism and with high frequency of cardiovascular morbidity and mortality. The prevalence seems to be related to the severity of psoriasis, as it occurs more frequently in patients presenting with large areas of the body affected with lesions. The aim of our work was to evaluate the development of dyslipidemia in psoriasis, and to look for a correlation between their levels and severity of diseases in which the risk factors and secondary causes of hyperlipidemia were excluded.

Methods: We evaluated the fasting lipid profile in twenty-four patients with mild to moderate psoriasis and twenty-four age and gender matched healthy subjects as the control group.

Results: Patients presented risk changes in lipid profile, serum total cholesterol (p<0.001), triglyceride (p<0.01), LDL-cholesterol (p<0.001), VLDL-cholesterol (p<0.01) and TC/HDL ratio (p<0.01) were found to be significantly higher than in control group. No significant statistical difference was observed between HDL levels of the two groups. Significant positive correlation in total cholesterol and LDL-cholesterol was found between mild and moderate psoriasis (PASI score) as compared with controls.

Conclusion: Our data suggest that psoriasis patients must be considered as a group at high risk for cardiovascular, since psoriasis per se seems to be associated with risk changes in the lipid profile. We conclude that psoriatic patients should be evaluated and followed up for the risk of hyperlipidemia and cardiovascular diseases.



Psoriasis, Serum lipids, PASI, CVD

Full Text:



Raychaudari SP, Farher EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001;15:16-7.

Vahlquist C, Michealsson G, Vessby B. Serum lipoproteins in middle-aged men with psoriasis. Acta Derm Venereol (stockh) 1987;67:12-5.

Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006;54:614-21.

Rocha-Pereira P, Santos-silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dyslipidemia and oxidative stress in mild and severe psoriasis as a risk for cardiovascular disease. Clinica Chimica Acta 2001;303:33-9.

Uyanik BS, Ariz OE, Gunduz K, Tanulka A, Durkan K. Serum lipids and apolipoproteins in patients with psoriasis. Clin Chem Lab Med 2002;40:65-8.

Vanizor Kural B, Orem A, Cimsit Y, Calapoglu M. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationship with oxidant and antioxidant system in patients with psoriasis. Clin Chim Acta 2003;328(1-2):71-82.

Utas S, Pasaoglu H, Muhtaroglu S, Unver U, Utas C, Kelestimur F. Serum lipid profile in patients with psoriasis. T Klin J Dermatol 1995;5:18-29.

Seckin D, Tokgozoglu L, Akkaya S. Are lipoprotein profile and lipoprotein(a) level altered in men with psoriasis? J Am Acad Dermatol 1994;31:445-9.

Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque type psoriasis. Dermatology 2005;210:194-9.

Mcgowan MW. An improved enzymatic method for determination of blood triglycerides by oxidase system. Clin Chem 1983;97:142-4.

Allan C. Enzymatic determination of total cholesterol. Clin Chem 1974;20:470-7.

Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.

Dibiasova M, Frohlich J. The plasma parameter log (TC/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma. Clin Biochem 2001;34:583-8.

Seishima M, Moris S, Noma A. Serum lipid and apolipoprotein levels in patients of psoriasis. Br J Dermatol 1994;130:738-42.

Gurkok F, Piskin S, Ekuklu G. Serum lipid and lipoprotein levels in psoriasis. Bull Leprosy 1999;30:105-11.

Proksch E. Antilipemic drug induced skin manifestations. Hautarzt 1995;2:76-80.

Mcdonald CD, Calabresi P. Psoriasis and vascular disease. Br J Dermatol 1978;99:469-75.

Vahlquist C, Berne B, Boberg M, Michaelsson G, Vessby B. The fatty acid spectrum in plasma and adipose tissue in patients with psoriasis. Arch Dermatol Res 1985;278:114-9.

Piskin S, Gurkok F, Ekuklu G, Senol M. Serum lipid levels in Psoriasis. Yonsei Med J 2003;44:24-6.

Mallbris L, Akre O, Granath F, Yin L, Lindelof B, et al. Increased risk for cardiovascular mortality in psoriasis in patients but not outpatients. Eur J Epidemiol 2004;19:225-30.

Fortniskaia ES, Torkhorskaia TI, Sharapova GIa, Lologuiova TK, Klinchnikova ZhI, Khalilov EM. Features of distribution of free and esterified cholesterol in the epidermis, biological membranes and plasma lipoproteins in psoriasis. Klin Lab Diagn 1996;4:38-43.

Orem A, Cimsit G, Deger O, Vanizor B. The significance of autoantibodies against oxidatively modified LDL in patients with psoriasis. Clin Chim Acta 1999;284:81-8.

Takeda H, Okuho M, Hoga M, Aizawa K. Lipid analysis of peripheral blood monocytes in psoriatic patients using fourier transform infrared microspectroscopy. J Dermatol 2001;28:303-11.

Schlaak F, Buslau M, Jochum W, et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994;102:145-9.

Frostegard J, Ulfgren AK, Nyberg P, et al. Cytokines expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage stimulating cytokines. Atherosclerosis 1999;145:33-43.